Data from newly acquired study could accelerate clinical development of CYBN’s CYB004 by nine months The pivotal study was designed with four primary objectives Cybin’s proprietary substance has potential to effectively treat anxiety disorders, including GAD and SAD Cybin (NEO: CYBN) (NYSE American: CYBN) has completed the acquisition of the largest dimethyltryptamine (“DMT”) study to date, … Continue reading “Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Completes Acquisition of Largest-Ever DMT Study”
Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various conditions, has announced preliminary data from a feasibility study using Kernel Flow. The results indicate that ketamine-induced changes in functional connectivity last for several days after administration of the substance. “Kernel Flow is the first easy-to-use, wearable … Continue reading “NetworkNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Unlocking ‘New Frontiers of Discovery’ with Kernel Flow”
Clinilabs Drug Development Corporation, a global, full-service contract research organization with deep expertise in central nervous system drug development, today announced commencement of enrollment in a phase 1/2a clinical trial of CYB003. Being developed by Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” CYB003 is the … Continue reading “NetworkNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) CYB003 Phase 1/2a Clinical Trial Through Clinilabs Begins Enrollment”
Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that, through its wholly-owned subsidiary Cybin IRL Limited, it has completed the acquisition of a phase 1 N,N-dimethyltryptamine (“DMT”) study from Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1). The DMT study, which is the largest to … Continue reading “NetworkNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Acquires DMT Study Expected to Accelerate Clinical Development Path of CYB004”
Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, a biotechnology company focused on progressing Psychedelics to Therapeutics(TM), and its wholly controlled subsidiary Adelia Therapeutics Inc., have announced the achievement of a key milestone. The milestone is identified as Y2, Q3 in the contribution agreement created between Adelia and Cybin when … Continue reading “NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), Adelia Announce Achievement of Milestone”
Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has received approval from the U.S. Food and Drug Administration (“FDA”) to proceed with its phase 1/2a first-in-human clinical trial evaluating CYB003; the company has received a “may proceed” letter and investigational new drug application (“IND”) clearance from the FDA. The approval … Continue reading “NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Moving Forward with Phase 1/2a Clinical Trial after Receiving Key FDA Approval”
Study indicates that ketamine-induced changes in functional connectivity last for several days after administration of the substance Kernel Flow gathers real-time functional brain activity during clinical and research studies evaluating psychedelic-based therapeutics Technology is “precisely what we need to accelerate the development of psychedelics into therapeutics,” says Cybin CEO New data confirms Cybin’s (NEO: CYBN) (NYSE … Continue reading “Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Reports Initial Results from Feasibility Study”
Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today reported recent business highlights and audited financial results for its fiscal year ended March 31, 2022. In addition, the company reiterated its anticipated pipeline and strategic milestones for the remainder of 2022. “Cybin made important progress across the board … Continue reading “NetworkNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Business Highlights, FY 2022 Results”
Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that its CEO Doug Drysdale will participate in a fireside chat and panel discussion at the H.C. Wainwright 1st Annual Mental Health Conference. The event is slated to take place at the Lotte New York Palace Hotel on … Continue reading “NetworkNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present at H.C. Wainwright 1st Annual Mental Health Conference”
Cybin (NYSE American: CYBN) (NEO: CYBN), a clinical-stage biopharmaceutical company committed to progressing Psychedelics to Therapeutics(TM), has joined the ranks of companies dedicated to finding and offering effective solutions to those suffering from mental health conditions. “The company announced that pilot results from its sponsored feasibility study evaluating Flow, Kernel’s quantitative neuroimaging technology, indicate that … Continue reading “NetworkNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Collaborating to Progress Mission to Create Safe, Effective Therapeutics”
